| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Age Related Macular Degeneration (AMD) is the main cause of legal blindness in the Western and Asian countries. The pathogenesis is the choroidal neovascularization (CNV) beneath the macula in the retina. The anti-VEGF therapy is the major treatment, but there still many intractable cases. We investigated the effectiveness of cytokines for CNV progression, and the correlation of genetic background and treatment effect to search new treatment. IL-27 was significantly reduced CNV progression by VEGF secretion blocking. And the injection of IL-17 blockage in CNV model mouse eye significantly reduced CNV progression. These cytokines are supposed to be one of the new treatment targets for AMD. Although we also investigated the correlation between some SNPs and the effectiveness of anti-VEGF therapy from clinical data, there aren't significantly differences between them for early treatment phase.
|
